Drug Trial Radar · NCT07733089
A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- Collaborators
- Centre for Human Drug Research, Netherlands; ICON Clinical Research
- First posted
- Jul 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.
Conditions
- Plaque Psoriasis
Interventions
ZP9830Drug
Participants will receive multiple doses of ZP9830. The dose frequency will depend on treatment arm
PlaceboDrug
Participants will receive multiple doses of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment Emergent Adverse Events (TEAEs)Time frame: From baseline (Day 1, predose) to follow-up (Day 85)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Human Drug Research
Leiden, South Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.